Literature DB >> 32439605

Long noncoding RNAs in nonalcoholic fatty liver disease and liver fibrosis: state-of-the-art and perspectives in diagnosis and treatment.

Antonio De Vincentis1, Zahra Rahmani2, Moises Muley1, Umberto Vespasiani-Gentilucci1, Sergio Ruggiero1, Parvin Zamani3, Tannaz Jamialahmadi4, Amirhossein Sahebkar5.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) significantly impacts global health. Despite considerable research, its pathophysiology remains partially unclear. In addition, selective serum biomarkers of disease diagnosis and progression are missing. Long noncoding RNAs (lncRNAs) are a heterogeneous group of ncRNAs with crucial roles in biological processes underlying the pathophysiology of different human diseases. Recent studies have shown that lncRNA could be associated with the genesis and progression of NAFLD towards the most severe forms. Although the field is still in its infancy, it is tempting to speculate that these transcripts could be used as both diagnostic and therapeutic targets. In this review, we summarize recent findings on lncRNAs in the complex research field of NAFLD.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Year:  2020        PMID: 32439605     DOI: 10.1016/j.drudis.2020.05.009

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  8 in total

1.  Silencing lncRNA TUG1 Alleviates LPS-Induced Mouse Hepatocyte Inflammation by Targeting miR-140/TNF.

Authors:  Qing-Min Liu; Li-Li Liu; Xi-Dong Li; Ping Tian; Hao Xu; Zeng-Lian Li; Li-Kun Wang
Journal:  Front Cell Dev Biol       Date:  2021-02-11

2.  LINC00466 Impacts Cell Proliferation, Metastasis and Sensitivity to Temozolomide of Glioma by Sponging miR-137 to Regulate PPP1R14B Expression.

Authors:  Mingfei Zhao; Yijie Shao; Jinfang Xu; Buyi Zhang; Chenguang Li; Jie Gong
Journal:  Onco Targets Ther       Date:  2021-02-19       Impact factor: 4.147

3.  The role and possible mechanism of the long noncoding RNA LINC01260 in nonalcoholic fatty liver disease.

Authors:  Xiaoxiao Ge; Tao Sun; Yanmei Zhang; Yongqing Li; Peng Gao; Dantong Zhang; Bingyang Zhang; Peijun Wang; Wanshan Ma; Sumei Lu
Journal:  Nutr Metab (Lond)       Date:  2022-01-12       Impact factor: 4.169

Review 4.  The Roles and Mechanisms of lncRNAs in Liver Fibrosis.

Authors:  Zhifa Wang; Xiaoke Yang; Siyu Gui; Fan Yang; Zhuo Cao; Rong Cheng; Xiaowei Xia; Chuanying Li
Journal:  Front Pharmacol       Date:  2021-11-24       Impact factor: 5.810

5.  Systematic Analysis of Long Non-Coding RNA Genes in Nonalcoholic Fatty Liver Disease.

Authors:  Mirolyuba Ilieva; James Dao; Henry E Miller; Jens Hedelund Madsen; Alexander J R Bishop; Sakari Kauppinen; Shizuka Uchida
Journal:  Noncoding RNA       Date:  2022-07-22

6.  LncRNA GAS5 Knockdown Mitigates Hepatic Lipid Accumulation via Regulating MiR-26a-5p/PDE4B to Activate cAMP/CREB Pathway.

Authors:  Shizan Xu; Yajie Wang; Zhengyang Li; Qian Hua; Miao Jiang; Xiaoming Fan
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-26       Impact factor: 6.055

Review 7.  Serum non-coding RNAs for diagnosis and stage of liver fibrosis.

Authors:  Chao Liu; Xueyun Hou; Kaixin Mo; Nannan Li; Cheng An; Guijian Liu; Zongdai Pan
Journal:  J Clin Lab Anal       Date:  2022-08-21       Impact factor: 3.124

Review 8.  Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis.

Authors:  Maryam Mahjoubin-Tehran; Antonio De Vincentis; Dimitri P Mikhailidis; Stephen L Atkin; Christos S Mantzoros; Tannaz Jamialahmadi; Amirhossein Sahebkar
Journal:  Mol Metab       Date:  2020-07-13       Impact factor: 7.422

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.